22 results on '"Hogerzeil, Hans V."'
Search Results
2. Availability, prices, and affordability of selected essential cancer medicines in a middle-income country - the case of Mexico.
- Author
-
Moye-Holz, Daniela, Ewen, Margaret, Dreser, Anahi, Bautista-Arredondo, Sergio, Soria-Saucedo, Rene, van Dijk, Jitse P., Reijneveld, Sijmen A., and Hogerzeil, Hans V.
- Subjects
MIDDLE-income countries ,NATIONAL health insurance ,PUBLIC sector ,PRIVATE sector ,PUBLIC hospitals - Abstract
Background: More alternatives have become available for the diagnosis and treatment of cancer in low- and middle-income countries. Because of increasing demands, governments are now facing a problem of limited affordability and availability of essential cancer medicines. Yet, precise information about the access to these medicines is limited, and the methodology is not very well developed. We assessed the availability and affordability of essential cancer medicines in Mexico, and compared their prices against those in other countries of the region.Methods: We surveyed 21 public hospitals and 19 private pharmacies in 8 states of Mexico. Data were collected on the availability and prices of 49 essential cancer medicines. Prices were compared against those in Chile, Peru, Brazil, Colombia and PAHO's Strategic Fund.Results: Of the various medicines, mean availability in public and private sector outlets was 61.2 and 67.5%, respectively. In the public sector, medicines covered by the public health insurance "People's Health Insurance" were more available. Only seven (public sector) and five (private sector) out of the 49 medicines were considered affordable. Public sector procurement prices were 41% lower than in other countries of the region.Conclusions: The availability of essential cancer medicines, in the public and private sector, falls below World Health Organization's 80% target. The affordability remains suboptimal as well. A national health insurance scheme could serve as a mechanism to improve access to cancer medicines in the public sector. Comprehensive pricing policies are warranted to improve the affordability of cancer medicines in the private sector. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
3. Legislating for universal access to medicines: a rights-based cross-national comparison of UHC laws in 16 countries.
- Author
-
Perehudoff, S Katrina, Alexandrov, Nikita V, and Hogerzeil, Hans V
- Subjects
LAW reform ,HIGH-income countries ,MIDDLE-income countries ,LEGAL rights ,MEDICAL care - Abstract
Universal health coverage (UHC) aims to ensure that all people have access to health services including essential medicines without risking financial hardship. Yet, in many low- and middle-income countries (LMICs) inadequate UHC fails to ensure universal access to medicines and protect the poor and vulnerable against catastrophic spending in the event of illness. A human rights approach to essential medicines in national UHC legislation could remedy these inequities. This study identifies and compares legal texts from national UHC legislation that promote universal access to medicines in the legislation of 16 mostly LMICs: Algeria, Chile, Colombia, Ghana, Indonesia, Jordan, Mexico, Morocco, Nigeria, Philippines, Rwanda, South Africa, Tanzania, Turkey, Tunisia and Uruguay. The assessment tool was developed based on WHO's policy guidelines for essential medicines and international human rights law; it consists of 12 principles in three domains: legal rights and obligations, good governance, and technical implementation. Relevant legislation was identified, mapped, collected and independently assessed by multi-disciplinary, multi-lingual teams. Legal rights and State obligations toward medicines are frequently codified in UHC law, while most good governance principles are less common. Some technical implementation principles are frequently embedded in national UHC law (i.e. pooled user contributions and financial coverage for the vulnerable), while others are infrequent (i.e. sufficient government financing) to almost absent (i.e. seeking international assistance and cooperation). Generally, upper-middle and high-income countries tended to embed explicit rights and obligations with clear boundaries, and universal mechanisms for accountability and redress in domestic law while less affluent countries took different approaches. This research presents national law makers with both a checklist and a wish list for legal reform for access to medicines, as well as examples of legal texts. It may support goal 7 of the WHO Medicines & Health Products Strategic Programme 2016-30 to develop model legislation for medicines reimbursement. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. The right to health as the basis for universal health coverage: A cross-national analysis of national medicines policies of 71 countries.
- Author
-
Perehudoff, S. Katrina, Alexandrov, Nikita V., and Hogerzeil, Hans V.
- Subjects
MARIJUANA ,DRUGS ,INTERNATIONAL cooperation ,PUBLIC finance - Abstract
Persistent barriers to universal access to medicines are limited social protection in the event of illness, inadequate financing for essential medicines, frequent stock-outs in the public sector, and high prices in the private sector. We argue that greater coherence between human rights law, national medicines policies, and universal health coverage schemes can address these barriers. We present a cross-national content analysis of national medicines policies from 71 countries published between 1990–2016. The World Health Organization’s (WHO) 2001 guidelines for developing and implementing a national medicines policy and all 71 national medicines policies were assessed on 12 principles, linking a health systems approach to essential medicines with international human rights law for medicines affordability and financing for vulnerable groups. National medicines policies most frequently contain measures for medicines selection and efficient spending/cost-effectiveness. Four principles (legal right to health; government financing; efficient spending; and financial protection of vulnerable populations) are significantly stronger in national medicines policies published after 2004 than before. Six principles have remained weak or absent: pooling user contributions, international cooperation, and four principles for good governance. Overall, South Africa (1996), Indonesia and South Sudan (2006), Philippines (2011–2016), Malaysia (2012), Somalia (2013), Afghanistan (2014), and Uganda (2015) include the most relevant texts and can be used as models for other settings. We conclude that WHO’s 2001 guidelines have guided the content and language of many subsequent national medicines policies. WHO and national policy makers can use these principles and the practical examples identified in our study to further align national medicines policies with human rights law and with Target 3.8 for universal access to essential medicines in the Sustainable Development Goals. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. The importance of insulin donations for children in 43 low- and middle-income countries.
- Author
-
Hogerzeil, Hans V. and Recourt, Sterre
- Subjects
TYPE 1 diabetes ,DIABETES in children ,INSULIN therapy ,INSULIN ,MIDDLE-income countries ,LOW-income countries ,CHARITABLE giving ,PHARMACEUTICAL industry - Abstract
Diabetes mellitus is rapidly becoming one of the major diseases affecting people's health globally. Over half of 100 million diabetes patients who need insulin to survive, especially in low- and middle-income countries (LMIC), are not able to get this medicine and die prematurely. Since 2000, insulin-producing companies have started support programmes with a component of insulin donations to children and youth with type 1 diabetes in 43 LMIC. Based on their experiences we conclude, contrary to common belief, that the diagnosis, treatment, and prevention of fatal complications in children with type 1 diabetes in LMIC are very possible in practice, with large improvements in survival, mean body weight, mean glucose levels, and frequency of complications. Medicine donations can never offer a sustainable solution and we now propose a ten-step transition process towards a fully sustainable national diabetes care and prevention programme for children and youth with diabetes type 1. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Access to essential medicines in 195 countries: A human rights approach to sustainable development.
- Author
-
Perehudoff, S. Katrina, Alexandrov, Nikita V., and Hogerzeil, Hans V.
- Subjects
HEALTH services accessibility laws ,HEALTH services accessibility ,HEALTH status indicators ,HEALTH systems agencies ,HUMAN rights ,RESEARCH funding ,STATISTICS ,SUSTAINABLE development ,DATA analysis ,DATA analysis software ,ESSENTIAL drugs - Abstract
In 2008 the UN Special Rapporteur on the Right to Health published 72 right to health indicators in 194 health systems. We present a follow-up report of eight indicators for access to medicines to serve as a reference point for progress towards SDG Target 3.8 on essential medicines. Data for these eight indicators in 2015 were collected and compared with the 2008 report. Between 2008 and 2015 we observed increased numbers of constitutions recognising access to medicines (7-13 countries), countries with a national medicine policy (118-122) and with a national list of essential medicines (78-107). Public spending on pharmaceuticals decreased or rose modestly in most of the 44 countries. Median availability of a basket of lowest-priced generics increased in the public (63%-70% n = 9 countries) and private (84%-92% n = 10) sectors. Median child immunisation rates remained constant for measles (around 90%) and improved for three doses of diphtheria-tetanus-pertussis (79%-86%). These eight indicators are useful and feasible, but should be further strengthened and expanded. Future monitoring exercises should use these indicators to screen progress and guide national governments' action to ensure universal access to essential medicines as part of the right to health. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.
- Author
-
Moye-Holz, Daniela, van Dijk, Jitse P., Reijneveld, Sijmen A., and Hogerzeil, Hans V.
- Subjects
PHARMACEUTICAL policy ,DRUGS ,PHARMACEUTICAL industry ,MEXICAN politics & government - Abstract
Background: The World Health Organization recommends establishing and implementing a national pharmaceutical policy (NPP) to guarantee effective and equitable access to medicines. Mexico has implemented several policy approaches to regulate the pharmaceutical sector, but it has no formal NPP. This article describes the approach that the Mexican government has taken to improve availability and affordability of essential medicines.Methods: Descriptive policy analysis of public pharmaceutical policy proposals and health action plans on the basis of publicly available data and health progress reports, with a focus on availability and affordability of medicines.Results: The government has implemented pooled procurement, price negotiations, and an information platform in the public sector to improve affordability and availability. The government mainly reports on the savings that these strategies have generated in the public expenditure but their full impact on availability and affordability has not been assessed.Conclusions: To increase availability and affordability of medicines in the public sector, the Mexican government has resorted on isolated strategies. In addition to efficient procurement, price negotiations and price information, other policy components and pricing interventions are needed. All these strategies should be included in a comprehensive NPP. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
8. Impacts of a new insurance benefit with capitated provider payment on healthcare utilization, expenditure and quality of medication prescribing in China.
- Author
-
Sun, Jing, Zhang, Xiaotian, Zhang, Zou, Wagner, Anita K., Ross‐Degnan, Dennis, and Hogerzeil, Hans V.
- Subjects
MEDICAL care costs ,HEALTH insurance ,OUTPATIENT medical care ,COST effectiveness ,MEDICAL research - Abstract
Copyright of Tropical Medicine & International Health is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2016
- Full Text
- View/download PDF
9. Achieving universal health coverage-the case of Zhuhai city.
- Author
-
Sun, Jing, Zhang, Xiao Tian, Zhang, Zou, and Hogerzeil, Hans V.
- Subjects
HEALTH insurance ,INSURANCE ,OUTPATIENT medical care ,MEDICAL care costs ,COST effectiveness - Abstract
Objective Universal health coverage cannot be achieved without evidence from research, which requires national and international support. We hope that our careful documentation of one of China's local experience in designing and implementing the basic health insurance coverage, and our analysis of how it helped to achieve universal health coverage, will inform other systems in China as well as other relevant countries on their way to universal coverage. Methods The paper first presents the development of Zhuhai's basic health insurance system chronologically; then comprehensively describes the background and the key components of the common disease outpatient benefit package; followed by a comparison with the common practices of outpatient benefit package of other areas of China and four neighboring countries. It also summarizes the strengths and weakness of the package, and lists the remaining research questions for future studies. Results The common disease outpatient benefit package of Zhuhai has helped to improve the universal health coverage of Zhuhai in the following aspects: securing all citizens' access to the common disease outpatient services under the basic health insurance coverage; containing the rapid growth of health expenditures; enhancing provider awareness of expenditure and encouraging cost-effective interventions through appropriate financial incentives; and shifting the focus from treatment to prevention and preventing the development of common diseases into serious conditions with high cost specialist services. The common disease outpatient benefit package greatly improved and strengthened the basic health insurance system through secured equal access to affordable outpatient care for common conditions. Conclusion Limited health resources are used more efficiently by pooling the risks and by implementing capitated provider payment, which enhances the cost awareness by health care providers, to improves efficiency and creates positive incentives for health professionals for using the most cost-effective health interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. A quiet revolution in global public health: The World Health Organization's Prequalification of Medicines Programme.
- Author
-
't Hoen, Ellen F M, Hogerzeil, Hans V, Quick, Jonathan D, and Sillo, Hiiti B
- Subjects
PUBLIC health ,MEDICAL care ,HIV ,PATENT medicines - Abstract
Problems with the quality of medicines abound in countries where regulatory and legal oversight are weak, where medicines are unaffordable to most, and where the official supply often fails to reach patients. Quality is important to ensure effective treatment, to maintain patient and health-care worker confidence in treatment, and to prevent the development of resistance. In 2001, the WHO established the Prequalification of Medicines Programme in response to the need to select good-quality medicines for UN procurement. Member States of the WHO had requested its assistance in assessing the quality of low-cost generic medicines that were becoming increasingly available especially in treatments for HIV/AIDS. From a public health perspective, WHO PQP's greatest achievement is improved quality of life-saving medicines used today by millions of people in developing countries. Prequalification has made it possible to believe that everyone in the world will have access to safe, effective, and affordable medicines. Yet despite its track record and recognized importance to health, funding for the programme remains uncertain. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. The concept of essential medicines: lessons for rich countries.
- Author
-
Hogerzeil, Hans V.
- Subjects
PHARMACEUTICAL policy ,DEVELOPING countries ,PUBLIC health ,HEALTH policy ,DRUGS ,PHARMACOLOGY ,DEVELOPED countries ,GOVERNMENT policy - Abstract
Examines the efforts of developing counties to design drug and medication programmes that people can afford. Key to the system which is the selection of essential medicines for public supply; Guidelines for choosing essential medicines; List from the World Health Organization which is revised every two years and how it helps contain costs while suppling valuable products; Two step process towards selection of the medications deemed essential; Thoughts on the concept of essential medicines and how it may apply to wealthy countries; National pharmaceutical policies of developing countries and which sections of the policies are relevant for developed countries. INSETS: Box 1: Definition of essential medicines;Box 2: Components of a national medicine policy...;Summary points.
- Published
- 2004
- Full Text
- View/download PDF
12. Could the WHO Model List of Essential Medicines Do More for the Safe and Appropriate Use of Injections?
- Author
-
Logez, Sophie M. D., Hutin, Yvan J. F., Holloway, Kathleen, Gray, Robin, and Hogerzeil, Hans V.
- Abstract
A national drug policy addressing the safe and appropriate use of injections is an important element to prevent overuse and unsafe use of injections. Because the World Health Organization World Health Organization Model List of Essential Medicines is a keystone of national drug policies, the authors examined the way it addresses injection practices. They reviewed the 11th World Health Organization Model List of Essential Medicines to collect information on (1) injectable medicines, (2) diluents, and (3) the recommendations regarding the procurement of injection devices. Of 306 active ingredients on the list, 135 (44%) arementioned in injectable form. Of these, 41 (30%) need diluents for reconstitution. The list does not mention the need to procure appropriate diluents, injection devices, and safety boxes in quantities that match the quantities of injectable medicines. In addition, the list provides limited information that can be used to forecast the needs of injection devices to administer the injectable medicines that are included in the list. Future revisions of the World Health Organization Model List of Essential Medicines should attempt to reduce the number of injectable formulations on the basis of evidence. In addition, the list should specify that when injectable medicines are being supplied, diluents, single-use syringes, and safety boxes should be supplied. The volume of syringes needed for administration should be specified for each injectable medication on the list to facilitate the forecasting of the needs of injection devices. [ABSTRACT FROM PUBLISHER]
- Published
- 2004
- Full Text
- View/download PDF
13. Prescription habits of dispensing and non-dispensing doctors in Zimbabwe.
- Author
-
Trap, Birna, Hansen, Ebba Holme, and Hogerzeil, Hans V
- Abstract
The number of dispensing doctors has increased in the last decade, but the implication of this trend on the quality of health care and drug use is unknown. We present a comparative drug utilization study of 29 dispensing doctors and 28 non-dispensing doctors in Zimbabwe based on standard indicators developed by the World Health Organization. Dispensing doctors prescribed significantly more drugs per patient than non-dispensing doctors (2.3 versus 1.7), injected more patients (28.4% versus 9.5%), and prescribed more antibiotics (0.72 versus 0.54) and mixtures (0.43 versus 0.25) per encounter. Dispensing doctors also spent significantly less time on each encounter (8.7 min versus 13.0 min) than their non-dispensing colleagues. The use of generic name, brand name and essential drugs did not differ significantly between the two groups of practitioners. Multivariate analyses controlling for gender, race, place of education, location of practice and patients seen per day showed that dispensing by doctors was associated with less clinically and economically appropriate prescribing. These findings suggest that the quality of health care--as related to drug use, patient safety and treatment cost--is lower with dispensing doctors than with non-dispensing doctors. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
14. Prescription habits of dispensing and non-dispensing doctors in Zimbabwe.
- Author
-
Trap, Birna, Hansen, Ebba Holme, and Hogerzeil, Hans V
- Abstract
The number of dispensing doctors has increased in the last decade, but the implication of this trend on the quality of health care and drug use is unknown. We present a comparative drug utilization study of 29 dispensing doctors and 28 non-dispensing doctors in Zimbabwe based on standard indicators developed by the World Health Organization. [ABSTRACT FROM PUBLISHER]
- Published
- 2002
- Full Text
- View/download PDF
15. Essential drugs for ration kits in developing countries.
- Author
-
HAAK, HILBRAND and HOGERZEIL, HANS V
- Abstract
Since the early 1980s drug ration kits have been used to improve the supply of essential drugs to rural health facilities in developing countries. This paper evaluates some of the experiences with kit systems in Angola, Bhutan, Democratic Yemen, Guinea-Conakry, Kenya, Mozambique, Sudan, Tanzania, Uganda and Zambia in relation to the selection of drugs for the kits and their quantities and cost. Data were collected through a review of published papers, annual reports and programme evaluations, by questionnaires among field staff and interviews with key experts. In comparing the 10 programmes, 21 drugs can be identified that are used in at least two-thirds of all kits. This list may be useful for evaluation and planning purposes. Six drugs (ORS, chloroquine and 4 antibiotics) usually account for over 60% of the cost of the kit. Careful monitoring of the price and quantities of these 6 drugs can therefore be very cost-effective. In the absence of reliable data on morbidity and drug needs in the initial phases of a kit system, the median drug quantities in kits from these 10 countries may serve as a starting point. Accumulating surpluses are sometimes perceived as a serious disadvantage of kit systems, ORS, benzyl-benzoate solution and iron tablets are the three drugs that have most frequently accumulated. These drugs are relatively cheap and usually have a long shelf-life; in most programmes they have been successfully redistributed to other health facilities while the kit content was being adapted. The overall financial loss due to accumulation of surpluses is therefore limited. Most programmes have reached a stable kit content within two years. [ABSTRACT FROM PUBLISHER]
- Published
- 1995
- Full Text
- View/download PDF
16. Computerized drug supply systems for developing countries.
- Author
-
Hogerzeil, Hans V and Manell, Per
- Abstract
The workload in a drug supply system in developing countries is more or less similar to that in developed countries. However, manpower and management skills are usually much less plentiful, while administrative procedures tend to be complicated and cumbersome. In view of the need for a careful use of limited resources and the fact that computers ('hardware') have become so much cheaper and easier to use, a description will be given of new computer programmes (‘software’) for drug registration, international drug tendering and inventory control that have specifically been developed for central authorities in developing countries, and that can run on simple personal computers. The most important characteristics of the programmes are their full compatibility with the international SWEDIS system which is used in many developed countries, the hardware- and language-independence, and the flexibility to change and expand the system according to need and potential. Common problems in the use of computers in developing countries are discussed, together with some suggested solutions. [ABSTRACT FROM PUBLISHER]
- Published
- 1989
17. Ten best readings in ... essential medicines.
- Author
-
Quick, Jonathan D and Hogerzeil, Hans V
- Published
- 2003
- Full Text
- View/download PDF
18. Ten best readings in . . . essential medicines.
- Author
-
Quick, Jonathan D and Hogerzeil, Hans V
- Published
- 2003
- Full Text
- View/download PDF
19. IDA and the concept of essential drugs.
- Author
-
Hogerzeil, Hans V.
- Subjects
DRUGS - Abstract
Describes the several areas for policy and technical development identified by the World Health Organization Department of Essential Drugs and Other Medicines. Benefits of national drug policies; Access to essential drugs; Drug regulation and quality.
- Published
- 1999
20. Access to innovative cancer medicines in a middle-income country - the case of Mexico.
- Author
-
Moye-Holz, Daniela, Soria Saucedo, Rene, van Dijk, Jitse P, Reijneveld, Sijmen A, and Hogerzeil, Hans V
- Subjects
CANCER treatment ,MEDICAL innovations - Abstract
Background: Cancer has become the third cause of death in Mexico. Treatment for cancer is often complex and lengthy. New and better medicines enter the market at high prices, which may limit access. Like most Latin American countries, Mexico has an essential cancer medicines list that includes innovative medicines. Their accessibility and use in the public sector remains unknown. Therefore, we describe the use, as a proxy of access, of innovative and essential cancer medicines in the public sector in Mexico, by insurance institution, and by five regions between 2010 to 2016. Methods: We used drug utilization research methods to assess the use of eight patented cancer medicines. Through the national transparency platform, we obtained data on the quantities of these medicines used in all public health facilities and social health insurance institutions and recalculated those figures into defined daily dose (DDD) per 1000 population per year. Results: Overall, the use of all medicines increased over the years, especially for trastuzumab, rituximab and imatinib. The use of innovative medicines was higher per population covered in social health insurance institutions than in governmental facilities. Throughout the study period, the Central region (including Mexico City) has used more medicines per population than the other regions. Conclusions: The use and access of some essential innovative cancer medicines has increased over the years, but remains unequal across insurance schemes and regions. Particularly, the Ministry of Health Insurance scheme and Northern and Western regions in the country would benefit from additional efforts to increase access to essential cancer medicines. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. Opposing the motion
- Author
-
Hogerzeil, Hans V.
- Published
- 2003
- Full Text
- View/download PDF
22. The quality and stability of essential drugs in rural Zimbabwe: Controlled longitudinal study.
- Author
-
Nazerali, Hanif and Hogerzeil, Hans V.
- Subjects
DRUGS - Abstract
Presents information on the results of a longitudinal study to measure the quality of essential drugs within rural Zimbabwe. Details on the study; Methodology used in the study; Findings of the study.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.